Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 1
2004 2
2005 4
2006 3
2007 5
2008 11
2009 11
2010 13
2011 12
2012 12
2013 16
2014 12
2015 5
2016 11
2017 24
2018 23
2019 25
2020 41
2021 39
2022 34
2023 33
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.
Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J. Narayanaswami P, et al. Neurology. 2021 Jan 19;96(3):114-122. doi: 10.1212/WNL.0000000000011124. Epub 2020 Nov 3. Neurology. 2021. PMID: 33144515 Free PMC article. Review.
OBJECTIVE: To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest evidence in the literature. METHODS: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to d …
OBJECTIVE: To update the 2016 formal consensus-based guidance for the management of myasthenia gravis (MG) based on the latest …
Rituximab treatment of myasthenia gravis: A systematic review.
Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Tandan R, et al. Muscle Nerve. 2017 Aug;56(2):185-196. doi: 10.1002/mus.25597. Epub 2017 Mar 21. Muscle Nerve. 2017. PMID: 28164324 Review.
Rituximab is a chimeric mouse/human anti-CD20 monoclonal immunoglobulin. We reviewed the efficacy and safety of rituximab in 169 myasthenia gravis (MG) patients from case reports and series. ...
Rituximab is a chimeric mouse/human anti-CD20 monoclonal immunoglobulin. We reviewed the efficacy and safety of rituximab …
Rituximab for the Treatment of Myasthenia Gravis: A 2021 Update.
Young C, McGill SC. Young C, et al. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr. PMID: 34255447 Free Books & Documents. Review.
The objective of this report is to review the clinical effectiveness and cost-effectiveness of rituximab therapy for the treatment of myasthenia gravis in those who are refractory to standard therapy. Additionally, this report aims to sum …
The objective of this report is to review the clinical effectiveness and cost-effectiveness of rituximab therapy for the tr …
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial.
Piehl F, Eriksson-Dufva A, Budzianowska A, Feresiadou A, Hansson W, Hietala MA, Håkansson I, Johansson R, Jons D, Kmezic I, Lindberg C, Lindh J, Lundin F, Nygren I, Punga AR, Press R, Samuelsson K, Sundström P, Wickberg O, Brauner S, Frisell T. Piehl F, et al. JAMA Neurol. 2022 Nov 1;79(11):1105-1112. doi: 10.1001/jamaneurol.2022.2887. JAMA Neurol. 2022. PMID: 36121672 Free PMC article.
IMPORTANCE: Rituximab is a third-line option for refractory generalized myasthenia gravis (MG) based on empirical evidence, but its effect in new-onset disease is unknown. ...Secondary end points, comparing changes in Myasthenia Gravis Activitie …
IMPORTANCE: Rituximab is a third-line option for refractory generalized myasthenia gravis (MG) based on empirical evide …
Myasthenia gravis: an update for the clinician.
Sieb JP. Sieb JP. Clin Exp Immunol. 2014 Mar;175(3):408-18. doi: 10.1111/cei.12217. Clin Exp Immunol. 2014. PMID: 24117026 Free PMC article. Review.
This paper provides a thorough overview of the current advances in diagnosis and therapy of myasthenia gravis (MG). Nowadays the term 'myasthenia gravis' includes heterogeneous autoimmune diseases, with a postsynaptic defect of neuromuscular tra …
This paper provides a thorough overview of the current advances in diagnosis and therapy of myasthenia gravis (MG). Now …
Novel Immunotherapies for Myasthenia Gravis.
Nair SS, Jacob S. Nair SS, et al. Immunotargets Ther. 2023 Apr 4;12:25-45. doi: 10.2147/ITT.S377056. eCollection 2023. Immunotargets Ther. 2023. PMID: 37038596 Free PMC article. Review.
Myasthenia gravis (MG), a prototype autoimmune neurological disease, had its therapy centred on corticosteroids, non-steroidal broad-spectrum immunotherapy and cholinesterase inhibitors for several decades. ...B cell-depleting agents, specifically rituxima …
Myasthenia gravis (MG), a prototype autoimmune neurological disease, had its therapy centred on corticosteroids, non-st …
Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.
Briani C, Visentin A. Briani C, et al. Neurotherapeutics. 2022 Apr;19(3):874-884. doi: 10.1007/s13311-022-01222-x. Epub 2022 Mar 28. Neurotherapeutics. 2022. PMID: 35349079 Free PMC article. Review.
In addition, the possible role of complement activation in the pathogenesis of chronic autoimmune neuropathies has brought into consideration drugs that can block the complement cascade, such as eculizumab, a monoclonal antibody already assessed in acute polyradiculoneuropathies, …
In addition, the possible role of complement activation in the pathogenesis of chronic autoimmune neuropathies has brought into consideratio …
Diagnosis and Management of Myasthenia Gravis.
Hehir MK 2nd, Li Y. Hehir MK 2nd, et al. Continuum (Minneap Minn). 2022 Dec 1;28(6):1615-1642. doi: 10.1212/CON.0000000000001161. Continuum (Minneap Minn). 2022. PMID: 36537972 Review.
PURPOSE OF REVIEW: This article reviews updated diagnostic procedures and currently available treatment modalities for myasthenia gravis (MG). RECENT FINDINGS: Patients with MG can be classified based on antibody status and their clinical presentation; tre …
PURPOSE OF REVIEW: This article reviews updated diagnostic procedures and currently available treatment modalities for myasthenia …
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.
Menon D, Bril V. Menon D, et al. Drugs. 2022 Jun;82(8):865-887. doi: 10.1007/s40265-022-01726-y. Epub 2022 May 31. Drugs. 2022. PMID: 35639288 Free PMC article. Review.
Myasthenia gravis (MG) is a chronic, fluctuating, antibody-mediated autoimmune disorder directed against the post-synaptic neuromuscular junctions of skeletal muscles, resulting in a wide spectrum of manifestations ranging from mild to potentially fatal. ...Although …
Myasthenia gravis (MG) is a chronic, fluctuating, antibody-mediated autoimmune disorder directed against the post-synaptic neu …
Guideline for the management of myasthenic syndromes.
Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K, Hoffmann S, Hoffmann HS, Jander S, Keller C, Marx A, Melms A, Melzer N, Müller-Felber W, Pawlitzki M, Rückert JC, Schneider-Gold C, Schoser B, Schreiner B, Schroeter M, Schubert B, Sieb JP, Zimprich F, Meisel A. Wiendl H, et al. Ther Adv Neurol Disord. 2023 Dec 26;16:17562864231213240. doi: 10.1177/17562864231213240. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 38152089 Free PMC article. Review.
Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS), and congenital myasthenic syndromes (CMS) represent an etiologically heterogeneous group of (very) rare chronic diseases. ...With the advent of modern, fast-acting immunomodulators, disease activity a …
Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS), and congenital myasthenic syndromes (CMS) represent an etiol …
326 results